Table 5.
Prognostic significance of RASSF1A methylation.
| Characteristics | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| RASSF1A methylation (yes vs. no) | 2.782 | 1.273–6.080 | 0.010 | 2.471 | 1.125–5.428 | 0.024 |
| Gender (male vs. female) | 1.543 | 0.742–3.205 | 0.245 | – | – | – |
| Tumor size (≥5 cm vs. <5 cm) | 0.745 | 0.361–1.537 | 0.425 | – | – | – |
| Tumor site (rectum vs. colon) | 0.880 | 0.426–1.822 | 0.732 | – | – | – |
| Tumor stage (III vs. II) | 1.557 | 0.758–3.200 | 0.228/ | – | – | – |
| Pathological differentiation (poor vs. well+moderate) | 1.998 | 0.949–4.207 | 0.068 | – | – | – |
| OR (CR+PR vs. SD+PD) | 3.035 | 1.237–7.444 | 0.015 | 2.678 | 1.085–6.610 | 0.033 |
OR – objective response; ‘–’ – no available data.